Hepatology forum · 2023
The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yaras Serkan, Demir Mehmet, Barutcu Sezgin, Yildirim Abdullah Emre, Gurel Selim, Ucbilek Enver, Kurtulmus Ilkce Akgun, Kayhan Meral Akdogan, Vatansever Sezgin, Adanir Haydar, Danis Nilay, Duman Serkan, Turan Ilker, Ari Derya, Kose Sukran, Alkim Huseyin, Harputluoglu Muhsin Murat, Dilber Feyza, Akyildiz Murat, Cosar Arif Mansur, Durak Serdar, Sirin Goktug, Kefeli Ayse, Gokcan Hale, Avcioglu Ufuk, Ayyildiz Talat, Sezgin Orhan, Akarsu Mesut, Dincer Dinc, Guzelbulut Fatih, Gunsar Fulya, Akarca Ulus Salih, Idilman Ramazan
Аннотация
BACKGROUND AND AIM: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).
MATERIALS AND METHODS: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.
RESULTS: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.
CONCLUSION: GLE/PIB is an effective and tolerable treatment in patients with CHC.
MATERIALS AND METHODS: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.
RESULTS: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.
CONCLUSION: GLE/PIB is an effective and tolerable treatment in patients with CHC.